GLP1R and diabetic kidney disease: Similar strategies are being considered in diabetic kidney disease, in which renal benefits of medication with potential anti-inflammatory effect (e.g. type 2 sodium-glucose cotransporter inhibitors, glucagon-like peptide-1 receptor agonists, renin-angiotensin-aldosterone system (RAAS) inhibitors) are evidently superior to those of medication that solely achieves tight glycemic control or reduction of arterial blood pressure (54).